Fulgent Genetics Debt to Equity Ratio 2015-2025 | FLGT
Current and historical debt to equity ratio values for Fulgent Genetics (FLGT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Fulgent Genetics debt/equity for the three months ending March 31, 2025 was 0.00.
| Fulgent Genetics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.08B | $1.12B | 0.07 |
| 2024-12-31 | $0.09B | $1.13B | 0.08 |
| 2024-09-30 | $0.10B | $1.14B | 0.09 |
| 2024-06-30 | $0.10B | $1.13B | 0.09 |
| 2024-03-31 | $0.10B | $1.13B | 0.09 |
| 2023-12-31 | $0.10B | $1.13B | 0.09 |
| 2023-09-30 | $0.10B | $1.26B | 0.08 |
| 2023-06-30 | $0.09B | $1.26B | 0.07 |
| 2023-03-31 | $0.11B | $1.27B | 0.09 |
| 2022-12-31 | $0.12B | $1.27B | 0.09 |
| 2022-09-30 | $0.12B | $1.28B | 0.10 |
| 2022-06-30 | $0.15B | $1.31B | 0.12 |
| 2022-03-31 | $0.15B | $1.31B | 0.12 |
| 2021-12-31 | $0.11B | $1.17B | 0.10 |
| 2021-09-30 | $0.16B | $1.04B | 0.15 |
| 2021-06-30 | $0.13B | $0.92B | 0.14 |
| 2021-03-31 | $0.20B | $0.80B | 0.25 |
| 2020-12-31 | $0.13B | $0.57B | 0.23 |
| 2020-09-30 | $0.06B | $0.19B | 0.32 |
| 2020-06-30 | $0.01B | $0.09B | 0.10 |
| 2020-03-31 | $0.01B | $0.08B | 0.10 |
| 2019-12-31 | $0.01B | $0.08B | 0.07 |
| 2019-09-30 | $0.01B | $0.06B | 0.12 |
| 2019-06-30 | $0.01B | $0.05B | 0.10 |
| 2019-03-31 | $0.01B | $0.05B | 0.11 |
| 2018-12-31 | $0.00B | $0.05B | 0.05 |
| 2018-09-30 | $0.00B | $0.05B | 0.04 |
| 2018-06-30 | $0.00B | $0.05B | 0.06 |
| 2018-03-31 | $0.00B | $0.05B | 0.05 |
| 2017-12-31 | $0.00B | $0.05B | 0.06 |
| 2017-09-30 | $0.00B | $0.06B | 0.06 |
| 2017-06-30 | $0.00B | $0.06B | 0.06 |
| 2017-03-31 | $0.00B | $0.06B | 0.06 |
| 2016-12-31 | $0.00B | $0.05B | 0.07 |
| 2016-09-30 | $0.01B | $0.02B | 0.32 |
| 2016-06-30 | $0.01B | $0.02B | 0.23 |
| 2016-03-31 | $0.00B | $0.00B | 0.00 |
| 2015-12-31 | $0.00B | 0.00 | |
| 2015-09-30 | $0.00B | $0.00B | 0.00 |
| 2015-06-30 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.00B | $0.00B | 0.26 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.646B | $0.283B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $39.174B | 54.11 |
| Hims & Hers Health (HIMS) | United States | $13.701B | 142.35 |
| Tempus AI (TEM) | United States | $10.751B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.508B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $4.426B | 69.15 |
| Privia Health (PRVA) | United States | $2.989B | 204.33 |
| Enovis (ENOV) | United States | $1.969B | 10.98 |
| Clover Health Investments (CLOV) | United States | $1.878B | 0.00 |
| Schrodinger (SDGR) | United States | $1.573B | 0.00 |
| Phreesia (PHR) | United States | $1.516B | 0.00 |
| Omnicell (OMCL) | United States | $1.348B | 23.78 |
| Azenta (AZTA) | United States | $1.294B | 60.15 |
| 10x Genomics (TXG) | United States | $1.118B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.566B | 0.00 |
| Talkspace (TALK) | United States | $0.502B | 150.00 |
| Veradigm (MDRX) | United States | $0.476B | 0.00 |
| Claritev (CTEV) | United States | $0.472B | 0.00 |
| Standard BioTools (LAB) | United States | $0.399B | 0.00 |
| TruBridge (TBRG) | United States | $0.374B | 830.67 |
| Health Catalyst (HCAT) | United States | $0.274B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.262B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.192B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.144B | 0.00 |
| Pulmonx (LUNG) | United States | $0.135B | 0.00 |
| American Well (AMWL) | United States | $0.118B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.102B | 0.00 |
| CareCloud (CCLD) | United States | $0.090B | 3.42 |
| Outset Medical (OM) | United States | $0.070B | 0.00 |
| 111 (YI) | China | $0.069B | 0.00 |
| Retrieve Medical Holdings (RMHI) | United States | $0.059B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.058B | 0.00 |
| HeartBeam (BEAT) | United States | $0.056B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.039B | 0.00 |
| Zhongchao (ZCMD) | China | $0.031B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.022B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.017B | 0.00 |
| Precipio (PRPO) | United States | $0.014B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.013B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.010B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.005B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.000B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |